Sagimet Biosciences Inc. - Series A
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.Company Description
- CEO
- David A. Happel
- Full Time Employees
- 16
- Sector
- Health technology
- Industry
- Pharmaceuticals: major
- Address
- 155 Bovet Road San Mateo CA United States 94402
- IPO Date
- Jul 14, 2023
- CIK
- 0001400118
- Website
- sagimet.com
- Similar Companies
- Business
- Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company specializing in the development of novel fatty acid synthase (FASN) inhibitors aimed at treating dysfunctional metabolic and fibrotic pathways in diseases caused by overproduction of the fatty acid palmitate. The company's primary products include its lead drug candidate denifanstat, an oral, once-daily selective FASN inhibitor in clinical development for metabolic dysfunction associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH). Denifanstat is also being evaluated in Phase 2 trials for moderate to severe acne vulgaris and in Phase 3 trials for recurrent glioblastoma multiforme in partnership with Ascletis Bioscience Co. Ltd. Additionally, Sagimet is developing TVB-3567, a second FASN inhibitor in early clinical trials for acne. The company operates mainly in the United States and China through collaborative partnerships and clinical trial sites. Founded in 2006, Sagimet Biosciences is headquartered in San Mateo, California. Recently, Sagimet has advanced its pipeline with a Phase 1 pharmacokinetic trial combining denifanstat and resmetirom in healthy adults, with topline data expected in the first half of 2026 to support further development in MASH patients with advanced liver fibrosis (F4). The license partner Ascletis has completed a pre-NDA consultation in China for denifanstat in moderate-to-severe acne following a successful Phase 3 trial that met all efficacy endpoints, supporting an upcoming NDA submission. Sagimet also commenced a first-in-human Phase 1 trial for TVB-3567 targeting acne, expanding its clinical portfolio. Financially, as of the third quarter of 2025, the company reported a net loss of $41.5 million over nine months with cash and marketable securities totaling approximately $125.5 million, enabling continued clinical development and strategic initiatives. These developments mark significant progress in Sagimet's expansion into multiple disease areas driven by fatty acid metabolism dysregulation.
Company News
Wall Street Analysts Think Sagimet Biosciences Inc. (SGMT) Could Surge 168.24%: Read This Before Placing a Bet
Sagimet Biosciences Announces First Patient Dosed in AURORA Phase 3 U.S. Clinical Trial of Denifanstat for Moderate to Severe Acne
Sagimet Biosciences: The U.S. Acne Trial Is A Replication Exercise, Not A Discovery Bet
Applied Dna Sciences (NASDAQ:BNBX) & Sagimet Biosciences (NASDAQ:SGMT) Head to Head Comparison
After Plunging 27.9% in 4 Weeks, Here's Why the Trend Might Reverse for Sagimet Biosciences Inc. (SGMT)
Sagimet To Present Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne and Mechanistic Data at the 2026 Fall Clinical Dermatology Conference
Sagimet Biosciences (NASDAQ:SGMT) Stock Rating Reaffirmed as “Buy” by HC Wainwright
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Sagimet Biosciences Highlights 52-Week Acne Data, Sets U.S. Phase III Trial Launch
Sagimet Biosciences Announces Closing of Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Biosciences Inc. (SGMT) Discusses 52-Week Phase 3 Data and U.S. Phase 3 Plans for Denifanstat in Moderate to Severe Acne Transcript
Sagimet Biosciences Surges Forward With Successful Acne Clinical Data and Capital Raise
Sagimet posts 52-week denifanstat acne data
Sagimet Biosciences Announces Pricing of $115.0 Million Underwritten Offering of Series A Common Stock and Pre-Funded Warrants
Sagimet Announces Positive Full 52-Week Results from License Partner Ascletis' Phase 3 Open-Label Extension Clinical Trial of Denifanstat in Acne Presented at EADV 2026
Sagimet Biosciences to Host Virtual KOL Event, “Denifanstat Update: 52-Week Data from Phase 3 Open-Label Extension in China and Planned AURORA Phase 3 Clinical Trial in US” on September 30, 2026
Sagimet Biosciences Announces Participation in Two Upcoming Investor Conferences
Sagimet Biosciences Inc. (NASDAQ:SGMT) Receives Average Rating of “Moderate Buy” from Analysts
Sagimet Biosciences Advances AURORA U.S. Phase 3 Trial of Denifanstat in Acne Toward Patient Enrollment in Q4 2026
Sagimet Biosciences Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)